We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.24%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.94B
AUM Growth
-$224M
Cap. Flow
-$1.92B
Cap. Flow %
-24.14%
Top 10 Hldgs %
74.98%
Holding
115
New
11
Increased
21
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$30.4M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$19.4M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$16.5M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$15.8M
5
XNPT
XENOPORT, INC.
XNPT
+$13.6M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$209M
2
QCOR
QUESTCOR PHARMA INC
QCOR
+$46.2M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$32.8M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.1M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 39.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
51
DELISTED
Array Biopharma Inc
ARRY
$5.12M 0.06%
1,433,797
– –
NVAX icon
52
Novavax
NVAX
$1.21B
$5.1M 0.06%
61,168
– –
XNCR icon
53
Xencor
XNCR
$1.45B
$5.05M 0.06%
542,363
– –
RXDX
54
DELISTED
Ignyta, Inc.
RXDX
$4.6M 0.06%
571,000
– –
IRWD icon
55
Ironwood Pharmaceuticals
IRWD
$586M
$4.49M 0.06%
413,315
-119,400
-22% -$1.37M
ACHN
56
DELISTED
Achillion Pharmaceuticals
ACHN
$4.38M 0.06%
438,337
– –
STML
57
DELISTED
Stemline Therapeutics, Inc.
STML
$4.22M 0.05%
338,671
– –
INFI
58
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.19M 0.05%
312,025
-312,025
-50% -$3.72M
AKTX
59
Akari Therapeutics
AKTX
$14.4M
$4.11M 0.05%
84
– –
LJPC
60
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.05M 0.05%
421,631
+200,000
+90% +$1.99M
EIGR
61
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.92M 0.05%
+833
New +$4.4M
IONS icon
62
Ionis Pharmaceuticals
IONS
$8.93B
$3.74M 0.05%
96,303
– –
ACGN
63
DELISTED
Aceragen Inc
ACGN
$3.71M 0.05%
11,918
+45
+0.4% +$16.2K
BDSI
64
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.59M 0.05%
210,021
-210,984
-50% -$3.06M
LGND icon
65
Ligand Pharmaceuticals
LGND
$5.77B
$3.45M 0.04%
117,660
– –
CYTR
66
DELISTED
CytRx Corp
CYTR
$3.43M 0.04%
225,000
– –
KPTI icon
67
Karyopharm Therapeutics
KPTI
$155M
$3.29M 0.04%
6,273
– –
LPCN icon
68
Lipocine
LPCN
$17.1M
$3.06M 0.04%
29,412
– –
ENTA icon
69
Enanta Pharmaceuticals
ENTA
$362M
$2.98M 0.04%
75,357
– –
FOLD
70
DELISTED
Amicus Therapeutics
FOLD
$2.87M 0.04%
481,697
– –
VXRT
71
DELISTED
Vaxart
VXRT
$2.73M 0.03%
100,628
– –
SGYP
72
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$2.71M 0.03%
973,245
-785,026
-45% -$2.85M
ZGNX
73
DELISTED
Zogenix, Inc.
ZGNX
$2.7M 0.03%
293,800
– –
AFMD
74
DELISTED
Affimed
AFMD
$2.52M 0.03%
+40,000
New +$2.5M
SAGE
75
DELISTED
Sage Therapeutics
SAGE
$2.36M 0.03%
+75,000
New +$2.17M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2014 Portfolio in Review

As of Q3 2014, Baker Bros. Advisors held 115 positions worth $7.94B, down 2.7% from $8.16B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Baker Bros. Advisors withdrew a net $1.92B in Q3 2014, closing 7 positions and reducing 12 holdings. Its most notable exit was INTERMUNE INC, an estimated $209M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 40% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $18.2M.

  • Baker Bros. Advisors's largest Q3 2014 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 201,856 shares worth $18.2M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q3 2014, an estimated $30.4M increase.
  • Baker Bros. Advisors's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $18.1M.
  • Baker Bros. Advisors fully exited INTERMUNE INC in Q3 2014, selling an estimated $209M.
  • Baker Bros. Advisors's ten largest holdings make up 75% of its $7.94B portfolio in Q3 2014.
  • Baker Bros. Advisors opened 11 new positions and closed 7 in Q3 2014.
  • Baker Bros. Advisors's portfolio value fell 2.7% quarter-over-quarter to $7.94B.

Based on Baker Bros. Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.